Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with suboptimal response to prior disease-modifying therapies: A primary analysis from the phase 3b CASTING single-arm, open-label trial.

导出 OA

翻译打印收藏纠错

作者： Patrick,Vermersch ^[1] ; Celia,Oreja-Guevara ^[2] ; Aksel,Siva ^[3] ; Bart,Van Wijmeersch ^[4] ; Heinz,Wiendl ^[5] ; Jens,Wuerfel ^[6] ; Regine,Buffels ^[7] ; Karen,Kadner ^[7] ; Thomas,Kuenzel ^[7] ; Giancarlo,Comi ^[8] ; CASTING Investigators

作者单位： Univ. Lille, Inserm U1172 LilNCog, CHU Lille, FHU Precise, Lille, France. ^[1] Hospital Clínico San Carlos, Madrid, Spain. ^[2] Istanbul University Cerrahpasa School of Medicine, Istanbul, Turkey. ^[3] University MS Centre, Pelt, Hasselt University, Hasselt, Belgium. ^[4] Department of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany. ^[5] Medical Image Analysis Center (MIAC AG), Department of Biomedical Engineering, University of Basel, Basel, Switzerland. ^[6] F. Hoffmann-La Roche Ltd, Basel, Switzerland. ^[7] Vita-Salute San Raffaele University, Milan Casa di Cura del Policlinico, Milan, Italy. ^[8]

关键词 disease activity disease-modifying therapies multiple sclerosis ocrelizumab relapsing-remitting multiple sclerosis

主题词人类(Humans);磁共振成像(Magnetic Resonance Imaging);多发性硬化(Multiple Sclerosis);多发性硬化, 复发缓解性(Multiple Sclerosis, Relapsing-Remitting);前瞻性研究(Prospective Studies)

DOI 10.1111/ene.15171

PMID 34748672

发布时间 2022-07-31

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交